Social anxiety disorder: A common, underrecognized mental disorder

American Family Physician

Volumn 60, Issue 8, 1999, Pages 2311-2322

  Bruce, Timothy J ^a   Saeed, Sy Atezaz ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLONAZEPAM; CLONIDINE; FLUVOXAMINE MALEATE; GABAPENTIN; IMIPRAMINE; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NADOLOL; NEFAZODONE; PAROXETINE; PHENELZINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TYRAMINE; UNCLASSIFIED DRUG;

BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DISABILITY; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; GENERAL PRACTICE; HUMAN; ORTHOSTATIC HYPOTENSION; PREVALENCE; REVIEW; SCREENING; SEDATION; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; TREATMENT PLANNING; WEIGHT GAIN;

EID: 0033571810     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:411-7.
2. Kessler RC, McGonagle DK, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 51:8-19.
3. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-8.
4. Scholing AE, Emmelkamp PM. Social phobia: nature and treatment. In: Leitenberg H, ed. Handbook of social and evaluation anxiety. New York: Plenum, 1990:269-324.
5. Ost LG, Hugdahl K. Acquisition of phobias and anxiety response patterns in clinical patients. Behav Res Ther 1981;19:439-47.
6. Katzelmick D, Kobak K, Helstad C, Greist J, Davidson J, De Laire T, et al. The direct and indirect costs of social phobia in managed care patients. Presented at the annual meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December,1998.
7. Sanderson WC, DiNardo PA, Rapee RM, Barlow DH. Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder. J Abnorm Psychol 1990;99:308-12.
8. Schneier FR, Martin LY, Liebowitz MR, Gorman JM, Fyer AJ. Alcohol abuse in social phobia. J Anx Disord 1989;3:15-23.
9. Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 1990;147:685-95.
10. Weiller E, Bisserbe JC, Boyer P, Lepine JP, Lecrubier Y. Social phobia in general health care: an unrecognized, undertreated, disabling disorder. Br J Psychiatry 1996;168:169-74.
11. Watson D, Friend R. Measurement of social-evaluative anxiety. J Consult Clin Psychol 1969;33:448-57.
12. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48: 938-45.
13. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
14. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161: 353-60.
15. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-9.
16. Schneier FR, Goetz D, Campeas R, Fallon B, Marchall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998;172:70-7.
17. Versiani M, Nardi AE, Mundim FD, Pinto S, Saboya E, Kovacs R. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 1996;11(suppl 13):83-8.
18. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998;59(suppl 17):54-60.
19. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-13.
20. Stein DJ, Berk M, Els C, Emsley RA, Gittelson L, Wilson D, et al. A double-blind placebo controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 1999;89(4):402-6.
21. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156(5):756-60.
22. Katzelnick D, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-71.
23. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: a double-blind placebo-controlled study with fluvoxamine. Psychopharmacol [Berl] 1994;115:128-34.
24. Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998; 49;79-82.
25. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8.
26. Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994;62:350-8.
27. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopnarmacol 1999;19(4):341-8.
28. Van Ameringen M, Mancini C, Oakman JM. Nefazodone in social phobia. J Clin Psychiatry 1999; 60(2):96-100.
29. Munjack DJ, Bruns J, Baltazar PL, Brown R, Leonard M, Nagy M. A pilot study of buspirone in the treatment of social phobia. J Anx Disord 1991;5:87-98.
30. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J, et al. Buspirone in social phobia. J Clin Psychopharmacol 1993;13:251-6.
31. van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997;58:164-8.
32. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-21.
33. Simpson HB, Schneier FR, Campeas RB, Marshall RD, Fallon BA, Davies S, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998;18:132-5.
34. Heimberg RG, Jester HR. Cognitive behavioral treatments: literature review. In: Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, eds. Social phobia: diagnosis, assessment, and treatment. New York: Guilford, 1995:261-309.
35. Juster HR, Heimberg RG. Social phobia: longitudinal course and long-term outcome of cognitive-behavioral treatment. Psychiatr Clin North Am 1995;18:821-42.
36. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, et al. Cognitive-behavioral group therapy vs phenelzine therapy for social phobia: long-term outcome. Arch Gen Psychiatry [In press.]